The DOI matches its Crossref record.
Reports of Esophageal Cancer with Oral Bisphosphonate Use
Open accessAbstract
To the Editor: Between the time of the initial marketing of alendronate in October 1995 through mid-May 2008, the Food and Drug Administration (FDA) received reports of 23 patients in the United States receiving a diagnosis of esophageal cancer, with alendronate (Fosamax, Merck) as the suspect drug (in 21 patients) or the concomitant drug (in 2 patients). No similar U.S. reports for other oral bisphosphonates were retrieved from the FDA's database for adverse-event reporting. Eight deaths were reported. Of the 23 patients, 18 (78%) were women; the median age was 74.0 years (mean, 71.8; based on 19 patients). Among the . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Rustgi, A. K., & El-Serag, H. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314530 · Cited by 1,243
Long-Term Use of Bisphosphonates in Osteoporosis
Watts, N. B., & Diab, D. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1947 · Cited by 542
Adverse effects of bisphosphonates: Implications for osteoporosis management
Kennel, K. A., & Drake, M. T. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60752-0 · Cited by 496
Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
McClung, M., Harris, S. T., Miller, P. D., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., Kendler, D. L., Yuen, C. K., & Lewiecki, E. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.023 · Cited by 451
Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers
McComsey, G. A., Tebas, P., Shane, E., Yin, M. T., Overton, E. T., Huang, J. S., Aldrovandi, G. M., Cardoso, S. W., Santana, J. L., & Brown, T. T. (2010) · Clinical Infectious Diseases · doi:10.1086/656412 · Cited by 396
Adverse Effects of Bisphosphonates: A Comparative Review
Adami, S., & Zamberlan, N. (1996) · Drug Safety · doi:10.2165/00002018-199614030-00003 · Cited by 377
Fliefel, R., Tröltzsch, M., Kühnisch, J., Ehrenfeld, M., & Otto, S. (2015) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.01.026 · Cited by 363
Bone Morphogenetic Protein-2 in Development and Bone Homeostasis
Halloran, D., Durbano, H. W., & Nohe, A. (2020) · Journal of Developmental Biology · doi:10.3390/jdb8030019 · Cited by 348
Bisphosphonate-associated adverse events
Papapetrou, P. D. (2009) · Hormones · doi:10.14310/horm.2002.1226 · Cited by 312
Benefits and risks of bisphosphonate therapy for osteoporosis
Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1027 · Cited by 290
Green, J., Czanner, G., Reeves, G., Watson, J., Wise, L., & Beral, V. (2010) · BMJ · doi:10.1136/bmj.c4444 · Cited by 275
Surface Engineering for Bone Implants: A Trend from Passive to Active Surfaces
Bosco, R., Van Den Beucken, J., Leeuwenburgh, S., & Jansen, J. (2012) · Coatings · doi:10.3390/coatings2030095 · Cited by 265
Metadata
- Authors
- Wysowski, D. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-01
- Volume
- 360
- Issue
- 1
- Pages
- 89-90
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2041371036
- Cited by
- 198
- References
- 0
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.